IN2014KN02366A - - Google Patents
Info
- Publication number
- IN2014KN02366A IN2014KN02366A IN2366KON2014A IN2014KN02366A IN 2014KN02366 A IN2014KN02366 A IN 2014KN02366A IN 2366KON2014 A IN2366KON2014 A IN 2366KON2014A IN 2014KN02366 A IN2014KN02366 A IN 2014KN02366A
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623203P | 2012-04-12 | 2012-04-12 | |
| US201261623414P | 2012-04-12 | 2012-04-12 | |
| PCT/US2013/031861 WO2013154752A1 (en) | 2012-04-12 | 2013-03-15 | A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02366A true IN2014KN02366A (en) | 2015-05-01 |
Family
ID=49328028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2366KON2014 IN2014KN02366A (en) | 2012-04-12 | 2014-10-27 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20150072962A1 (en) |
| EP (2) | EP2836502B1 (en) |
| JP (4) | JP6125610B2 (en) |
| KR (1) | KR102180485B1 (en) |
| CN (2) | CN104220450B (en) |
| AU (2) | AU2013246435B2 (en) |
| BR (1) | BR112014025081B1 (en) |
| CA (1) | CA2867694C (en) |
| DK (1) | DK2836502T3 (en) |
| EA (1) | EA026683B1 (en) |
| ES (1) | ES2641841T3 (en) |
| HK (1) | HK1202294A1 (en) |
| HU (1) | HUE035073T2 (en) |
| IL (1) | IL234892B (en) |
| IN (1) | IN2014KN02366A (en) |
| MX (1) | MX357046B (en) |
| PL (1) | PL2836502T3 (en) |
| PT (1) | PT2836502T (en) |
| SI (1) | SI2836502T1 (en) |
| WO (1) | WO2013154752A1 (en) |
| ZA (1) | ZA201406981B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| EA026683B1 (en) * | 2012-04-12 | 2017-05-31 | Вирджиния Коммонвелт Юниверсити | CHOLESTEROL METABOLITE, 5-CHOLESTEN-3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS |
| SI3086793T1 (en) | 2013-12-24 | 2022-10-28 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction |
| TWI547280B (en) * | 2014-04-24 | 2016-09-01 | 長弘生物科技股份有限公司 | Stable pharmaceutical composition |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| JP2017530174A (en) * | 2014-10-10 | 2017-10-12 | ヴァージニア コモンウェルス ユニバーシティ | Oxygenated cholesterol sulfate for treating disorders caused by at least one of impaired leptin activity and lipid accumulation disorders |
| EP3237377A4 (en) * | 2014-12-24 | 2018-08-22 | Kyoto University | Vitamin d3 derivatives and pharmaceutical use thereof |
| AU2017306140A1 (en) | 2016-08-02 | 2019-02-21 | Durect Corporation | Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions |
| CA3031224A1 (en) | 2016-08-02 | 2018-02-08 | Shunlin Ren | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| TW201818946A (en) * | 2016-08-02 | 2018-06-01 | 美商杜瑞克公司 | Compositions comprising at least one oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride, and methods for their use |
| CA3050001A1 (en) | 2017-01-13 | 2018-07-19 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
| KR101892577B1 (en) | 2017-04-21 | 2018-08-28 | 부산대학교 산학협력단 | Composition for preventing or treating atherosclerosis comprising reblastatin derivation or pharmaceutical acceptable salts thereof |
| CN107286160A (en) * | 2017-06-05 | 2017-10-24 | 毛佳婧 | A kind of preparation method of the piperidines of Antihepatitis medicament and pyrido pyrazoles Zn complex |
| US20200197471A1 (en) * | 2017-08-31 | 2020-06-25 | Ariel Scientific Innovations Ltd | S. spinosum extract for treating fatty liver disease |
| BR112022005039A2 (en) * | 2019-09-30 | 2022-06-21 | Durect Corp | Treatment of alcoholic hepatitis |
| CN112294827B (en) * | 2020-11-12 | 2021-12-24 | 四川大学华西医院 | Application of 5-cholesten-3 beta-alcohol sulfate |
| KR20230061860A (en) | 2021-10-29 | 2023-05-09 | 부산대학교 산학협력단 | Pharmaceutical composition for preventing or treating atherosclerosis comprising a xanthine derivative as an active ingredient |
| WO2024008614A1 (en) * | 2022-07-08 | 2024-01-11 | Société des Produits Nestlé S.A. | Use of 25-hydroxycholesterol for diabetic treatment and/or prevention |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1189922A4 (en) * | 1999-04-30 | 2002-08-14 | Arch Dev Corp | Steroid derivatives |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| WO2007095462A2 (en) | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| WO2011077245A2 (en) * | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| EA026683B1 (en) * | 2012-04-12 | 2017-05-31 | Вирджиния Коммонвелт Юниверсити | CHOLESTEROL METABOLITE, 5-CHOLESTEN-3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS |
-
2013
- 2013-03-15 EA EA201491859A patent/EA026683B1/en unknown
- 2013-03-15 EP EP13775974.2A patent/EP2836502B1/en active Active
- 2013-03-15 WO PCT/US2013/031861 patent/WO2013154752A1/en active Application Filing
- 2013-03-15 ES ES13775974.2T patent/ES2641841T3/en active Active
- 2013-03-15 PT PT137759742T patent/PT2836502T/en unknown
- 2013-03-15 CN CN201380019476.3A patent/CN104220450B/en active Active
- 2013-03-15 KR KR1020147031567A patent/KR102180485B1/en active IP Right Grant
- 2013-03-15 PL PL13775974T patent/PL2836502T3/en unknown
- 2013-03-15 US US14/391,929 patent/US20150072962A1/en not_active Abandoned
- 2013-03-15 CN CN201610412359.9A patent/CN106083976B/en active Active
- 2013-03-15 EP EP17167122.5A patent/EP3239163A1/en not_active Withdrawn
- 2013-03-15 SI SI201330794T patent/SI2836502T1/en unknown
- 2013-03-15 BR BR112014025081-2A patent/BR112014025081B1/en not_active IP Right Cessation
- 2013-03-15 JP JP2015505762A patent/JP6125610B2/en not_active Expired - Fee Related
- 2013-03-15 HU HUE13775974A patent/HUE035073T2/en unknown
- 2013-03-15 DK DK13775974.2T patent/DK2836502T3/en active
- 2013-03-15 AU AU2013246435A patent/AU2013246435B2/en not_active Ceased
- 2013-03-15 MX MX2014012324A patent/MX357046B/en active IP Right Grant
- 2013-03-15 CA CA2867694A patent/CA2867694C/en active Active
-
2014
- 2014-09-25 ZA ZA2014/06981A patent/ZA201406981B/en unknown
- 2014-09-28 IL IL234892A patent/IL234892B/en active IP Right Grant
- 2014-10-27 IN IN2366KON2014 patent/IN2014KN02366A/en unknown
-
2015
- 2015-03-17 HK HK15102737.7A patent/HK1202294A1/en unknown
-
2016
- 2016-08-19 US US15/241,171 patent/US20160355544A1/en not_active Abandoned
-
2017
- 2017-04-05 JP JP2017074866A patent/JP2017160213A/en active Pending
- 2017-10-10 US US15/728,827 patent/US20180127457A1/en not_active Abandoned
- 2017-11-30 AU AU2017268646A patent/AU2017268646B2/en not_active Ceased
-
2018
- 2018-09-25 US US16/140,964 patent/US20190135856A1/en not_active Abandoned
-
2019
- 2019-01-10 JP JP2019002297A patent/JP2019089777A/en not_active Withdrawn
- 2019-10-10 US US16/599,044 patent/US20200157140A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,647 patent/US20210238219A1/en not_active Abandoned
-
2021
- 2021-05-14 JP JP2021082520A patent/JP2021138713A/en active Pending